JPH0753397A - Mutagenicity-inhibiting agent - Google Patents

Abstract

PURPOSE:To provide a mutagenicity inhibiting agent containing a juice, etc., obtained from a plant belonging to the Aloe L. in the Liliaceae as the active ingredient, having a good activity-inhibiting action against environmental mutagens existing in foods, exhaust gases, dejections, etc., excellent in safety and anticarcinogenic property, and useful for medicines, etc. CONSTITUTION:The objective inhibiting agent contains as the active ingredient a juice or extract obtained from a plant belonging to the Aloe L. in the Liliaceae and containing aloe-emodin of the formula.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to a mutagenicity inhibitor, the object of which is to show a very good activity inhibitory action against environmental mutagens present in food, exhaust gas, feces, etc. It is an object of the present invention to provide a highly safe mutagenicity inhibitor that can be effectively used as a drug and a food for specified health uses for the purpose of preventing cancer.

[0002]

2. Description of the Related Art The mortality rate due to cancer in Japan has topped stroke for several years, and approximately 150,000 people die of cancer annually. This means that one in four Japanese will die of cancer, and controlling cancer is a major national problem. In cancer, the cells themselves forming an individual are transformed into cancer cells by some mechanism, the cancer cells proliferate indefinitely, and finally the host (individual) is killed. In experimental animals such as rats and mice, it is known that a virus causes cancer, but in humans, the occurrence of a virus is extremely rare, and most of them are caused by chemical carcinogens existing in the environment. It is thought to occur because somatic genes are damaged. This chemical carcinogen
Most of them are mutagens. A mutagen is a substance that induces mutations at a higher frequency than naturally occurring mutations in bacteria, mammalian cells, etc.
It is divided into a base pair substitution type in which one of the base pairs is replaced with another base pair and a frame shift type mutagen which adds or deletes a base pair.

Many mutagens have been found in our living environment. A typical example thereof is benzo (α) pyrene (benzpyrene) present in cigarette smoke or automobile exhaust gas. Also, in cooked meat and fish products, there exist mutagens that exhibit a higher mutation activity than the above-mentioned benzpyrene. These are mutagens produced by heating amino acids and proteins, and tryptophan produces 3-amino-1,4-dimethyl-5H-pyrido [4,3-b] indole (Trp-P-1) and 3-Amino-1-methyl-5H-pyrido [4,3-b]
Indole (Trp-P-2) was converted from glutamic acid to 2-amino-6-methyldipyrido [1,2-a: 3 ′,
2′-d] imidazole (Glu-P-1) and 2-amino-6-dipyrido [1,2-a: 3 ′, 2′-d] imidazole (Glu-P-2) are respectively produced by heating. It is known. It has also been reported that in everyday foods, a mutagen precursor is present in soy sauce and broad bean that are consumed by many Japanese people. Further, strong mutagens such as 1-nitropyrene and 1,6-nitropyrene are also detected in diesel exhaust gas and used engine oil of gasoline passenger cars.

[0004]

As described above, various mutagens exist in foods and the atmosphere, which are closely related to our daily lives. However, these foods and air are indispensable for our survival. Therefore, for our survival, the industry
Suppress mutagenicity induced by the mutagen,
It has been urgently desired to create a highly safe mutagenicity inhibitor that can be effectively used as a drug or a food for specified health uses for the purpose of preventing or controlling cancer, which is a national problem.

[0005]

[MEANS FOR SOLVING THE PROBLEMS] The present invention provides a mutagenicity inhibitor characterized in that a juice or extract obtained from a plant of the family Liliaceae (Aloe L.) is used as an active ingredient. This solves the above-mentioned conventional problems.

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION The constitution of the mutagenicity inhibitor according to the present invention will be described in detail below. In the present invention, plants belonging to the genus Aloe L. of the lily family are used as starting materials. There are many Aloe L. plants, and there are currently about 300 of them, and their distribution is mainly in the drylands from southern to eastern Africa. Typical examples of this are Aloe arborescens Mill. And Cape aloe (A
loe ferox Mill.), Socotra aloe (Aloe perryi
B _AKER ), Curacao Aloe (Aloe barbadensis Mil
l.) and Natal aloe (Aloe bainesii T _H ).

Further, Aloe L. plants cultivated in Japan can also be preferably used. A specific example of this is "Aloe a
rborescens var.), "Red crocodile" (A. africana), "Blue crocodile"
(A. ferox), "Aloe vera" (A. vera), "Polka dot Nishiki"
(A. khamiensis), "Aloe vera var. Sinensis" (Av
era var. chinencis), “Glossy Nishiki” (A. speciosa), “Soapon Rokai” (Aloe saponaria), “Nanban Nishiki” (A.ar
borescens var. nataliensis), "Sorei Nishiki" (A. delto
ideodonta), "Ishihana Nishiki" (A. dolomitica), "Minami Nishiki"
(A.spuria), "Fuji Nishiki" (A. andongensis), "Horei Nishiki"
(A. lineata var. Muirii), `` Waveguide '' (A. aristata va
r.), "Hoshirinnishiki", "Choshigori Orihime" (A.bellatula M.),
"A. latifolia", "A. succotrin"
a), "Snow Makeup" (A. albiflora M.), "Takage Nishiki" (A. dawe
i), "A. cremnophila", "A. lutes"
cens), "Peacock Nishiki" (A. pretoriensis), "Ishitama Nishiki" (Al
ineata), “blue storm” (A.striatula), “Higashi no Nishiki” (A.co
mmutata), “Child of the Hermit” (A. albiflora var.), “Reimivi Nishiki” (A. recurviflora), “Eru Nishiki” (A.eru), “Ryumon Nishiki” (A. rubrolutea), “Saint Nishiki” '' (A. rupestris), `` Hagoromonishiki '' (A. cooperi), `` A. black jem '', `` Komotialoe '' (A. bulbillifera M.), `` Tenjin Nishiki '' (A. acut
iissiima M.), "Otome Musha" (A. affinis), "Green Devil"
(A.greenii), "Shikou Nishiki", "Yumeden Nishiki" (A.mudenensi
s), “Hanage Nishiki” (A.tomentosa), “Eryu Nishiki” (A.eru va)
r. maculata), "Uchiura Nishiki" (A.dyeri), "Yachiyo Nishiki"
(A.microstigma), `` Gurennishiki '' (A.greatheadii), `` Ishidamasen '' (A.lineaca), `` Dairyunishiki '' (A.chabaudii), `` Amanohoshinishiki '' (A.runcinata), "Kureho" (A. sp.), "Yukimusume"
(A.pratensis), "Aokijo" (A.spinosissima), "Hoshinhoshi" (A.vossii), "Lubryfrom" (A.delaetii),
"Aoba Nishiki" (A. nobilis), "Cao Nishiki" (A. fosteri),
"Celadon Nishiki" (A. sp), "Heavenly Star Nishiki" (A. runcinata),
"Omine Nishiki" (A.doessanda), "Otachi Nishiki" (A.camper
i), “Sandenjin” (A.candelabrm), “Onio Nishiki” (A.spect
abilis), "Kanshirou" (A.distans), "Woman's figure" (A.mut
abilis), "Nightless Castle" (A. mitriformis), "Nora Senjo"
(A. comosa), "Chunrei Nishiki" (A. sessiliflora), "Sayaki Nishiki" (A. pixii), "Namio Nishiki" (A. davyiana), "Jogashima"
(A.closby), "Sumidagawa" (A. steudneri), "Otome Nishiki"
(A. giobuligemma), "Oha Nishiki" (A. suprafoliata),
"Jade ball fan" (A. plicatilis var. Minima), "Torayoshi Nishiki"
(A. traskiii), "Sasayuri Nishiki" (A. ciliaris), "Tahana Nishiki" (A. thompsoniae), "Taishan Nishiki" (A. bainesii),
"A. hereroensis", "Kayo Chiyoda" (A. variega
ta), `` choja Nishiki '' (A. parvibracteara), `` Chihaya castle '' (A.
sp), “Aloe Kaiser”, “Long Life Nishiki” (A. longibractea
ta), "Shigeru Nishiki" (A. striata), "Aloe Praecox", "Ao Nishiki" (A. tenuior), "A. humil" (A. humil)
is), "Huangsei Nishiki" (A.sp.), "Needenjin" (A.excesia),
"Black sword" (A. cryptopoda), "Oni no Gloves" (A. castane
a), "Baombe" (A.vaombe), "Shoho Nishiki" (A.sinkatan)
a), "Hoshikasumi" (A.verdoorniae), "Dinosaur Mountain" (A.brecifo)
lia var. depressa), "Gokuraku Nishiki" (A. arenicola), "Aose Nishiki" (A. spiniflora), "Miroku Nishiki", "Himeryuyama",
Examples include “Mt. Toyoko”, “Hisuiden”, “Mikanishiki”, and any of them can be suitably used without any particular limitation.

In the present invention, the genus Aloe (Al
oe L.) Squeezed juice or extract obtained from any one kind or two or more kinds of plants is used as an active ingredient. The extraction solvent for obtaining the extract is not particularly limited, and water or alcohols such as methanol and ethanol, acetone, ethyl acetate, ketones such as diethyl ether, and one or two polar solvents such as ester and ether. The above mixed solvents, or one or more mixed solvents of non-polar solvents such as n-hexane, petroleum ether, ligroin, cyclohexane, carbon tetrachloride, chloroform, dichloromethane, toluene, benzene, and polar solvents and non-polar A mixed solvent with a solvent and the like can be preferably used.

In the juice or extract obtained from the plant of the genus Aloe L., aloe-emodin represented by the general formula 2 (Chemical Formula 2), which is a kind of anthraquinone compound, is used. The present inventors have found in the course of earnest research that this aloe-emodin exhibits extremely effective inhibitory activity against mutagens.

[0010]

[Chemical 2]

The squeezed juice or extract obtained from the plant of the genus Aloe (Aloe L.) as described above is dried to obtain an extract powder, and the extract powder is used as an active ingredient and the mutagenic inhibitor according to the present invention. can do. The dosage form of this mutagenicity inhibitor may be in the form of solution, soft extract, or powder, and is not particularly limited. Also, the administration form is not particularly limited, and may be appropriately added with arbitrary excipients, auxiliaries and the like, and may be used as a drug such as a powder, granules, tablets, capsules, syrups, etc. according to a conventional method for producing a preparation. The food for specified health use, which is expected to have a mutagenicity-suppressing effect, may be drinks, beverages such as juices, confectionery, and other foods, and is not particularly limited.

[0012]

EXAMPLES The mutagenicity inhibitor of the present invention will be described in more detail below with reference to Examples and Test Examples. However, the present invention is not limited to the following examples.

(1) Preparation of Aloe (Aloe) genus plant extract 3.0 kg of dried leaf of Aloe arborescens Mill. Was soaked in 26 kg of methanol and extraction was carried out at room temperature for 7 days. After 7 days, the resulting extract was suction filtered (To
yo No. 2) and 19.89 Kg of filtrate were obtained. The obtained filtrate is 45 ℃
The solution was concentrated under reduced pressure under the following temperature conditions to obtain 565.44 g of concentrated solution. The obtained concentrated filtrate was used as a component of Sample 1. Further, 2 liters of water and 2.5 liters of petroleum ether were added to 450 g of the obtained concentrated filtrate, and water-petroleum ether separation and extraction were carried out to obtain 225 g of a petroleum ether-soluble portion and a water-soluble portion ( The separation and extraction here were repeated 4 times). The obtained concentrated liquid of the petroleum ether-soluble portion was used as Sample 2. In addition, the concentrated liquid of the water-soluble portion was used as Sample 3. Further, the petroleum ether-soluble part (Sample 2) was concentrated under reduced pressure (165.18 g), and the concentrate was further subjected to silica gel column chromatography [No. 9385 Kieselgel 60 (230
-400 mesh), MERC]. At the time of this purification fractionation, chloroform solvent as a solvent, chloroform: methanol = 5: 1 solvent,
Five kinds of fractions A to E (fractions A to E) as shown in Table 1 were obtained by using three kinds of solvents each including a methanol solvent.

[0014]

[Table 1]

Samples 1 to 3 obtained by the above process
And the fractions A to E were each subjected to a mutagenicity-suppressing test described below, and Sample 1 in which mutagenicity-suppressing activity was observed was Example 1, Sample 2 was Example 2, Fraction C was Example 3, Fraction D. Example 4
In addition, sample 3 having a negative mutagenicity-suppressing activity was designated as Comparative Example 1, fraction A as Comparative Example 2, fraction B as Comparative Example 3, and fraction C as Comparative Example 4. A schematic diagram of these extraction steps is shown in FIG. (Note that (+) in the figure indicates that suppressive activity was observed in the mutagenicity suppressive test described below).

(2) Examination of pharmacological effect (mutagenicity suppressing effect)
A mutagenicity inhibition test was performed in combination with the above extraction step. The mutagenicity inhibition test was carried out using a histidine (His) -requiring Salmonella strain TA98 as an indicator of the inhibitory effect on the mutagen Trp-P-2 detected from the burning of food. [Ames variant (plate method); His - test whether cause back mutations to His ⁺ mutants of Salmonella ^(unable to synthesize histidine) by contact with the specimen] Further, mutagen Trp-P -2 undergoes metabolic activation to become N-OH-Trp-P-2, which is known to exhibit mutagenicity. Therefore, metabolic activation enzyme S-9m
The test was conducted by adding ix.

A) Preparation of Salmonella TA98 strain SDB liquid medium preparation NaCl 0.5 g, Bacto nutrient broth (Difco) 0.8 g
Was dissolved in 100 ml of distilled water, adjusted to pH 7.0 and sterilized in an autoclave. Inoculation / enrichment Salmonella TA98 in the sterilized SDB liquid medium
0.2 ml of the stock solution was added to inoculate the cells, and the cells were cultured at 37 ° C for 18 hours with shaking to enrich the cells. Preparation and storage TA98 bacterial culture was centrifuged (0 ℃, 3,500rpm, 15
The cells were separated for 11 minutes using an 11 cm rotor). The dilution ratio of all the solutions was determined so that the OD value was 0.5, and the solution was diluted with phosphate buffer and dimethylsulfoxide (DMSO) (final concentration 12%). This diluted solution was placed in a 4 ml vial and stored at -80 ° C until the mutagenicity inhibition test was performed. This is TA9
Eight bacterial stock solutions were used.

B) Preparation of MBB agar medium (MBB agar medium formulation) i. Bacto ager (Difco) 30 g distilled water 1,860 g ii. MM (Modified Voger Bonner's 20X) medium (NH ₄ ) ₂ SO ₄ 20 g KH ₂ PO ₄ 200g MgSO ₄・ 7H ₂ 0 2g Na ₃ C ₆ H ₅ O ₇ (Sodium citrate) 10g KOH 34.5g / 900ml (* Adjust the total volume to 1 liter after adjusting pH to 7.0 with KOH aqueous solution) iii.DB solution Bacto nutrient broth (Difco) 400ml Distilled water 40ml (* Adjusted to pH 6.8 to 7.0) iv.40% Glucose solution Glucose (Anhydrous) 20g Distilled water 30ml v.Biotin solution Biotin 4mg Srerilized water 40ml (* Prepared for use) (MBB Agar Medium Preparation Method) After the above i to v were respectively prepared, they were separately sterilized in an autoclave. After v was prepared, it was sterilized by filtration in a clean bench. After cooling the i to about 70 ° C., ii 100 ml, iii 2
0 ml, iv 20 ml and v 2 ml were added aseptically and mixed well. About 25 ml of the above medium was poured into a 9 cm dish that had been sterilized by heat in advance to prepare a plate medium. After air-drying the surface of the plate medium, it was stored for 1 day or more until it was used for a mutagenicity inhibition test.

C) Mutagenicity Inhibition Test Into 3.0 ml of soft agar (* 1) kept at 50 ° C., the component (* 2) 1 extracted in the above Examples and Comparative Examples was used.
100 μl of thawed Salmonella TA98 stock solution
100 μl of Trp-P-2 aqueous solution (1.5 μg / ml)
50 μl of S-9mix (rat liver extract) (* 3)
After adding 0 μl each and stirring rapidly, it was spread on the MBB agar medium prepared in advance. Similarly, dimethyl sulfoxide (DMS) was used in place of the aloe extract samples.
O) was added in an amount of 100 μl in the same manner, and this was used as a control. Make 3 plates of each sample
It was cultured at 7 ° C for 3 days. Hi mutated after culture
The number of s ⁺ revartrant colonies was measured, and the average was used to determine the mutation suppression rate based on the following formula (1). The results are shown in Table 2. Similarly, aloe emodin (al
The mutagenicity suppression test was also performed for oe-emodin).
The results are shown in Table 3. * 1: NaCl 3.0g, Ager 3.5g dissolved in 500ml distilled water, sterilized by autoclave and kept at 50 ° C * 2: DMSO was used to dilute each component * 3: S-9 ( Oriental Yeast Co., Ltd. (* 3-1) 1 ml of Cofactor-I (Oriental Yeast Co., Ltd. (* 3-2)) dissolved in 9 ml of distilled water was sterilized by filtration. * 3-1: As an inducer, phenobarbital (PB) and 5,
Supernatant fraction obtained by homogenizing rat male liver co-administered with 6-benzoflavone (BF) and centrifuging at 9,000 × g * 3-2: Composition MgCl ₂ / 6H ₂ O 16.3mg NADH 30.5mg KCl 24.6 _{mg NA 2 HPO 4 119.6mg G-} 6-P 17.0mg NAH 2 PO 4 · 2H 2 O 24.7mg NADPH 36.2mg C: number of colonies in the control of His ⁺ revartrant S: number of colonies His ⁺ revartrant of each sample

[0020]

[Table 2]

[Table 3]

D) Viable cell count measurement test Salmonella TA98 stock solution with phosphate buffer (* 4) 1
^Serially diluted to 0-5. In 3.0 ml of soft agar (* 5) kept at 50 ° C., 100 μl of the components obtained in each of the examples and comparative examples and 100 μl of this diluted solution (D
(Diluted with MSO) was added, and the mixture was quickly stirred and then spread on an MBB agar plate medium prepared in advance. Similarly, 100 μl of dimethyl sulfoxide (DMSO) was added in place of each of the aloe extract samples, and this was used as a control. Prepare 3 plates of each plate, 37 ℃
The cells were cultured for 3 days. After culturing, the viable cell count was measured, and the average thereof was calculated to obtain Salmonella TA9 as a component of each Example and Comparative Example.
The presence or absence of toxicity to 8 bacteria was tested. The results are shown in Table 4. Similarly, the viable cell count of aloe-emodin was also measured. The results are shown in Table 5. * 4: Dissolve 14.3g of Na ₂ PO ₄ · 12H ₂ O and 3.6g of KH ₂ PO _{4 in} 1 liter of distilled water and adjust to pH 7.0 * 5: 3.0g of NaCl and 3.5g of Ager in 500ml of distilled water Dissolved in, sterilized by autoclave, and kept at 50 ℃

[0022]

[Table 4]

[Table 5]

(3) Identification of Active Ingredients As a result of the mutagenicity inhibition test, identification of the ingredients contained in Example 3 which showed a particularly high mutagenicity inhibition rate was carried out by thin layer chromatography (TLC) analysis and infrared absorption. Spectrum (IR) analysis, ultraviolet absorption spectrum (UV) analysis,
Performed by high performance liquid chromatography (HPLC) analysis.

Thin layer chromatography (TLC) analysis Art5715, Kieselgel 60F254 0.25 mm thin layer (Merck)
An appropriate amount of the component obtained in Example 3 was spotted on the above. Also, as a standard product, aloe-emodin
[Funakoshi] was spotted on the same thin layer. As a developing solvent, a) chloroform: methanol = 25: 1
When a color was developed with a 50% sulfuric acid solution using, the same single yellow spot was observed in both Example 3 and the control as shown in FIG. 2 (Rf values were both 0.56). Further, when b) chloroform was used as a developing solvent and color was developed with a 50% sulfuric acid solution, as shown in FIG. 3, the same yellow single spot was observed for both the components of Example 3 and the control (Rf value). Were both 0.10.)

Infrared (IR) absorption spectrum analysis The components obtained in Example 3 were subjected to infrared absorption spectrum analysis (ν cm ^-1 ; KBr) to give 335.
0 (-OH), 1672 (-C = O), 1625 (-C)
= C), 1570, 1456, 1389, 1288, 1
Absorption was observed in the vicinity of 272 (cm ^-1 ) (see FIG. 4), which completely matched the spectrum of the standard product [aloe-emodin (Funakoshi)].

Ultraviolet (UV) Absorption Spectrum Analysis The components obtained in Example 3 were subjected to ultraviolet absorption spectrum analysis (λ max nm; MeOH), and as a result, 430
nm, 276.5 nm, 254 nm and 225 nm were observed (see FIG. 5), and the spectra were completely in agreement with those of the standard product [aloe-emodin (Funakoshi)]. In addition, this spectrum shows the absorption values of the aloe-emodin described in the literature in the ultraviolet region (430, 276.
5, 254, 225 nm).

High Performance Liquid Chromatography (HPL
C) Analysis The components obtained in Example 3 were analyzed by HPLC. Analysis conditions are stationary phase column: Lichrospher 100 RP-1
8.5 μm (manufactured by MERCK), mobile solvent: 40% acetonitrile, flow rate: 1.0 ml / min., Ultraviolet absorption: 254 nm,
It was carried out at a temperature of 45 ° C. The same analysis was carried out using aloe-emodin (manufactured by Funakoshi Co., Ltd.) as a standard product. The results are shown in FIG. 6 (Example 3) and FIG.
(Standard product) In the analysis chart shown in FIG.
The Retension time of the substance obtained in Example 3 was 10.2 min. While the standard substance was 10.38 min.
It was suggested that both are likely to be the same substance.

Fractions A to E (Comparative Examples 2 to 4 and Examples 3 to 4) obtained by further purifying the petroleum ether phase fraction obtained in Example 2 by silica gel column chromatography Was analyzed by thin layer chromatography (TLC) to identify the active ingredient contained in the petroleum ether phase. Fractions A to E (Comparative Examples 2 to 4, Examples 3 to 4) and aloe-emodin (manufactured by Funakoshi Co., Ltd.) as a standard product were respectively applied on a thin layer [Art 5715, Kieselgel 60F254 (manufactured by MERCK Co.)]. After spotting an appropriate amount and developing with chloroform, color was developed with 50% sulfuric acid. The result is shown in FIG. Both Fraction C (Comparative Example 4) and Fraction D (Example 3) were subjected to silica gel column chromatography to obtain the same solvent (chloroform: methanol =
5: 1), but as can be seen in FIG. 8, in Fraction D (Example 3), the same yellow spot (1) at the same Rf value as the standard (Aloe emodin). Has been found and has been shown to be aloe-emodin. However, in Fraction C (Comparative Example 4), such a yellow spot (1) was not observed, and a dark green spot (2) was observed at another position. Therefore, even with the same developing solvent, due to the difference in the adsorptivity to silica gel, the components contained in Fraction C (Comparative Example 4) and Fraction D (Example 3) are different, and Fraction D (Example 3) is aloe-emodin. Has been suggested.

As a result of the above analytical test, the component obtained in Example 3 was identified to be aloe-emodin represented by the general formula 3 (Chemical Formula 3).

[Chemical 3]

As is clear from the results shown in Tables 2 and 3, the yellow-tailed aloe (Aloearborescens Mil) according to the examples was used.
l.) Extracts have been found to have mutagenic activity. In addition, aloe-emodin has also been found to have high mutation-suppressing activity at concentrations above a certain level.
As is clear from the results in Table 4, Aloe arb
The effect of the toxicity of the orescens Mill.) extract on Salmonella TA98 was hardly observed. As is clear from the results shown in Table 5, almost no effect of aloe-emodin on the toxicity of Salmonella TA98 was observed.

[0031]

INDUSTRIAL APPLICABILITY As described above in detail, the present invention is a mutagenic inhibitor characterized in that the juice or extract obtained from the plant of the family Liliaceae (Aloe L.) is used as an active ingredient. Therefore, as is clear from the results of the above-mentioned test examples, it exhibits extremely effective inhibitory activity against mutagenic substances present in the environment such as foods and air, and is a national issue of cancer. It can be effectively used as a drug or a food for specified health uses for the purpose of prevention of occurrence, and since its active ingredient is derived from a natural product, it has an excellent effect that it is a highly safe mutagenic inhibitor. .

[Brief description of drawings]

FIG. 1 shows the aloe (Alo) used in the examples of the present invention.
FIG. 3 is a schematic diagram showing a step of obtaining an eL.) extract.

FIG. 2 is an explanatory diagram showing the results of thin layer chromatography analysis of the aloe extract and standard product obtained in Example 3 of the present invention (developing solvent; chloroform: methanol = 2).
5: 1).

FIG. 3 is an explanatory view showing the results of thin layer chromatography analysis of the aloe extract and standard product obtained in Example 3 of the present invention (developing solvent: chloroform).

FIG. 4 is a chart showing the results of infrared (IR) absorption spectrum analysis of the aloe extract obtained in Example 3 of the present invention.

FIG. 5 is a chart showing the results of ultraviolet (UV) absorption spectrum analysis of the aloe extract obtained in Example 3 of the present invention.

FIG. 6 is a chart showing the results of high performance liquid chromatography (HPLC) analysis of the aloe extract obtained in Example 3 of the present invention.

FIG. 7 is a chart showing the results of high performance liquid chromatography (HPLC) analysis of a standard product (aloe emodin).

FIG. 8: Fractions A to E (Comparative Examples 2 to 4, Examples 3 to 4) and standards obtained by further purifying the petroleum ether phase fraction obtained in Example 2 by silica gel column chromatography. It is explanatory drawing which shows the result of the thin layer chromatography analysis of a product (Aloe emodin) (developing solvent; chloroform, coloring reagent; 50% sulfuric acid).

Claims (2)

[Claims] 1. A mutagenic inhibitor comprising a juice or extract obtained from a plant of the genus Aloe L. of the family Liliaceae as an active ingredient. 2. The mutagenic inhibitor according to claim 1, wherein the active ingredient is aloe-emodin represented by the general formula 1 (Formula 1). [Chemical 1]